UBE2L3 and systemic lupus erythematosus: Because UBE2L3 is highly abundant in plasmablasts and plasma cells, our study provides primary evidence that UBE2L3 could potentially be a therapeutic target in SLE and possibly for other autoimmune diseases (Table S1) or plasma cell diseases such as multiple myeloma.